GLP-1
Biomarker4 papers2 findings
- Human trial3
Interventions
2Feijoa powder
no changein humans1Low certainty
1 study
Feijoa powder
no changein humans1Low certainty
Feijoa powder has no effect on GLP-1 in humans.
“GLP-1 concentrations did not differ between groups. However, no change in GLP-1 was observed between the treatments.”
Human trialoverweight and prediabetes12 weeksn = 39
Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial · medRxiv · 22 Sep 2026 · Preprint
Resistance training
upin humans1+47%Low certainty
1 study
Resistance training
upin humans1+47%Low certainty
Resistance training increases GLP-1 in humans (+46.9%).
Human trialin elderly patients with primary osteoporosis complicated with muscle atrophy32-weekn = 98
Precise resistance training alleviates osteosarcopenia via the GLP-1/myostatin path: a 32-week randomized controlled trial and molecular mechanism study · Archives of physiology and biochemistry · 17 Sep 2026
Funding
National Institute of Diabetes and Digestive and Kidney DiseasesUS$2.6mNational Institute on AgingUS$1.2mNational Heart, Lung, and Blood InstituteUS$817.5k14 grants since 2015
National Institute of Diabetes and Digestive and Kidney DiseasesApplied Biotechnology InstituteUS$288.2k2026–2028
The effect of endogenous GLP-1 secretion on islet function in vivo
National Institute of Diabetes and Digestive and Kidney DiseasesMayo Clinic RochesterUS$727.8k2020–2030
Developing GLP-1 Producing Genetically Engineered Probiotics for Treatment of Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney DiseasesMedosome Biotec, LlcUS$356.3k2026–2027
Hydrogen Sulfide and GLP-1 Combination Therapy to Treat HFpEF
National Heart, Lung, and Blood InstituteCedars-Sinai Medical CenterUS$727.6k2025–2029
Impact of GLP-1 Receptor Agonists on Sarcopenia in Older Adults
National Institute on AgingArizona State University-tempe CampusUS$436.2k2026–2028
Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation
National Institute on Drug AbuseUniversity of Southern CaliforniaUS$2.9m2025–2028
Elucidating the pharmacogenetics of the response to GLP-1 receptor agonists for type 2 diabetes
National Institute of Diabetes and Digestive and Kidney DiseasesMassachusetts General HospitalUS$190.8k2022–2027
Bone metabolism in adolescents undergoing GLP-1 receptor agonist therapy
National Institute of Child Health and Human DevelopmentUniversity of VirginiaUS$471.8k2015–2030
National Institute of Diabetes and Digestive and Kidney DiseasesMassachusetts General HospitalUS$79.5k2026–2029
National Institute of Diabetes and Digestive and Kidney DiseasesMayo Clinic RochesterUS$322.8k2025–2028
Latest
363Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy
New insights into the pathogenesis of osteoporosis and the translational approach to personalized therapy
Innovative holistic treatment for CKM: what lies ahead?
Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide
GLP-1 agonists linked to lower dementia risk after COVID-19
GLP-1 receptor agonist initiation was associated with a lower hazard of incident dementia than DPP-4 inhibitors (HR 0.64) in diabetic COVID-19…GLP-1 receptor agonist initiation was associated with a lower hazard of incident dementia than DPP-4 inhibitors (HR 0.64) in diabetic COVID-19 survivors.